Treatment with Tyrosine Kinase Inhibitors in Patients with Lung Cancer
Abstract
Introduction: Tyrosine kinase receptor mutation plays a paramount role in non-small cell lung cancer because of its implications in the prognosis and treatment of the disease.
Objective: To show the survival of patients with lung carcinoma with an epidermal growth factor receptor mutation treated with tyrosine kinase inhibitors at the clinical oncology service of Hermanos Ameijeiras Clinical-Surgical Hospital.
Methods: A descriptive and retrospective study (n=29) was carried out from 2017 to 2020 with non-small cell lung cancer with an epidermal growth factor receptor mutation in Hermanos Ameijeiras Hospital, determined by polymerase chain reaction. Variables related to clinical-pathological characteristics and treatment were studied. Survival was evaluated using Kaplan-Meier. The log-rank and Breslow test was used for curve comparison, with a significance level of 0.05 and a confidence interval of 95 %.
Results: Seventeen patients received gefitinib and twelve received osimertinib. The median age was 67 years. 55.2 % were women and 44.8 % were men. 72.4 % were non-smokers, with an adenocarcinoma as the histological subtype in 82.6 % and at stage IV (72.4 %), the most common metastatic sites being contralateral lung and pleura, accounting for 37.9 % and 34.5 %, respectively. Nonextrathoracic metastatic disease predominated, accounting for 58.3 %; while the most common type of deletion corresponded to exon 19, accounting for 58.6 %. The disease control rate (partial response and stable disease) was 69%. Median overall survival was 31.3 months (95 % CI: 3.4-59.2) and progression-free survival was 13 months (95 % CI: .0-32.9).
Conclusions: Patient characteristics, as well as overall and progression-free survival, were similar to those published in international studies.
Keywords: lung adenocarcinoma; epidermal growth factor receptor expression; tyrosine kinase inhibitors.
Downloads
References
. Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, et al. Pan-Asian Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(2):171–210. DOI:10.1093/annonc/mdy554
Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, et al. The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thoracic Oncol. 2017;12(7):1109–21. DOI:10.1016/j.jtho.2017.04.011
Daga A, Ansari A, Patel S, Mirza S, Rawal R, Umrania V. Current drugs and drug targets in non – small cell lung cancer: Limitations and opportunities. Asian Pac J Cancer Prev. 2015;16(10): 4147- 4156. DOI: 10.7314/apjcp.2015.16.10.4147
8. De Castro J, Belda C, Perona R. Carcinoma de pulmón no microcítico. Oncología Clínica. 3ª edición. Madrid: Momento médico Iberamericana, s.l. 2010. p.63 – 91.
9. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2015;11(4):556-65. DOI: 10.1016/j.jtho.2015.12.103.
Paz-Ares LG, de Marinis F, Dediu M. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:2895-902. DOI: 10.1200 / JCO.2012.47.1102
Perol M, Chouaid C, Perol D, Barlési F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012;30:3516-24. DOI: 10.1200 / JCO.2011.39.9782
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550. DOI: 10.1056 / NEJMoa061884
Downloads
Published
How to Cite
Issue
Section
License
Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.
Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.
El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.
